Groundbreaking emergency
treatment for vasospasm & stroke.
Two-minute non-invasive
magnetic stimulation treatment.
US FDA Humanitarian Use Designation
confirmed for vasospasm.
Testing device eggectiveness
against migraines.
Currently pursuing Humanitarian Device Exemption.CAUTION – Investigational device. Not yet approved by US FDA for sale. Limited by United States law to investigational use.
A groundbreaking
emergency treatment
for stroke & vasospasm
- Easy, non-invasive, magnetic stimulation treatment
- Relaxes cerebral arteries, allowing superior blood perfusion
- Just one, 2-minute stimulation
- Goal 1: Expand the “Golden Hour” for stroke victims
- Goal 2: Earlier treatments in ICUs, emergency departments, and ambulances
Our Leadership Team
Jeffrey Lietzke
CEO
20 years of medtech founding, commercialization, and exit experience.
Emilio Sacristan, PhD
PhD Chief Science Officer, Co-Founder and Director
Co-inventor of the CereFast.
Stephanie Harrington, MS
Chief Clinical and Regulatory Officer
20 years of experience in the medical device industry.
Guy Jean L. Savoir
Director
Businessman, entrepreneur and investor in the pharmaceutical and health-care industries.
Dr. John Andrefsky
Clinical Advisory Board
Vascular Neurologist at University Hospitals. Fellowship-trained in neurocritical care, Cleveland Clinic.
Pre-clinical &
Clinical Testing
- Completed healthy human subjects trial establishing safety, tolerability, and dose response
- Vasospasm patients’ human pilot trial: all patients resolved vasospasm (fully or partially) and all survived after a single stimulation
- NIH-sponsored early feasibility clinical trial for treatment of ischemic stroke in the emergency department – first patient enrollment expected during Q3 2024
- Ten scientific papers published to date
Increase in brain perfusion index after one stimulation in blue; and after two stimulations 120 minutes apart in red.
Approach to Market
Publications
- Facial nerve stimulation as a future treatment for ischemic stroke
- Effects of Noninvasive Facial Nerve Stimulation in the Dog Middle Cerebral Artery Occlusion Model of Ischemic Stroke
- Restored Brain Perfusion after Non-Invasive Stimulation of the Facial Nerve in a Canine Stroke Model
- Effect of pulsed magnetic stimulation of the facial nerve on cerebral blood flow
Groundbreaking emergency
treatment for vasospasm & stroke.
Two-minute non-invasive
magnetic stimulation treatment.
US FDA Humanitarian Use Designation
confirmed for vasospasm.
Testing device eggectiveness
against migraines.
Currently pursuing Humanitarian Device Exemption.
CAUTION – Investigational device. Not yet approved by US FDA for sale.
Limited by United States law to investigational use.
A groundbreaking emergency
treatment for stroke & vasospasm
- Easy, non-invasive, magnetic stimulation treatment
- Relaxes cerebral arteries, allowing superior blood perfusion
- Just one, 2-minute stimulation
- Goal 1: Expand the “Golden Hour” for stroke victims
- Goal 2: Earlier treatments in ICUs, emergency departments, and ambulances
Our Leadership Team
Jeffrey Lietzke
CEO
20 years of medtech founding, commercialization, and exit experience.
Emilio Sacristan, PhD
PhD Chief Science Officer, Co-Founder and Director
Co-inventor of the CereFast.
Stephanie Harrington, MS
Chief Clinical and Regulatory Officer
20 years of experience in the medical device industry.
Guy Jean L. Savoir
Director
Businessman, entrepreneur and investor in the pharmaceutical and health-care industries.
Dr. John Andrefsky
Clinical Advisory Board
Vascular Neurologist at University Hospitals. Fellowship-trained in neurocritical care, Cleveland Clinic.
Pre-clinical & Clinical Testing
- Completed healthy human subjects trial establishing safety, tolerability, and dose response
- Vasospasm patients’ human pilot trial: all patients resolved vasospasm (fully or partially) and all survived after a single stimulation
- NIH-sponsored early feasibility clinical trial for treatment of ischemic stroke in the emergency department – first patient enrollment expected during Q3 2024
- Ten scientific papers published to date
Increase in brain perfusion index after one stimulation in blue; and after two stimulations 120 minutes apart in red.
Approach to Market
Publications
- Facial nerve stimulation as a future treatment for ischemic stroke
- Effects of Noninvasive Facial Nerve Stimulation in the Dog Middle Cerebral Artery Occlusion Model of Ischemic Stroke
- Restored Brain Perfusion after Non-Invasive Stimulation of the Facial Nerve in a Canine Stroke Model
- Effect of pulsed magnetic stimulation of the facial nerve on cerebral blood flow
Groundbreaking emergency
treatment for vasospasm & stroke.
Two-minute non-invasive
magnetic stimulation treatment.
US FDA Humanitarian Use Designation
confirmed for vasospasm.
Testing device eggectiveness
against migraines.
Currently pursuing Humanitarian Device Exemption.
CAUTION – Investigational device. Not yet approved by US FDA for sale.
Limited by United States law to investigational use.
A groundbreaking
emergency treatment for stroke & vasospasm
- Easy, non-invasive, magnetic stimulation treatment
- Relaxes cerebral arteries, allowing superior blood perfusion
- Just one, 2-minute stimulation
- Goal 1: Expand the “Golden Hour” for stroke victims
- Goal 2: Earlier treatments in ICUs, emergency departments, and ambulances
Our Leadership Team
Jeffrey Lietzke
CEO
20 years of medtech founding, commercialization, and exit experience.
Emilio Sacristan, PhD
PhD Chief Science Officer, Co-Founder and Director
Co-inventor of the CereFast.
Stephanie Harrington, MS
Chief Clinical and Regulatory Officer
20 years of experience in the medical device industry.
Guy Jean L. Savoir
Director
Businessman, entrepreneur and investor in the pharmaceutical and health-care industries.
Dr. John Andrefsky
Clinical Advisory Board
Vascular Neurologist at University Hospitals. Fellowship-trained in neurocritical care, Clevland Clinic.
Pre-clinical & Clinical Testing
- Completed healthy human subjects trial establishing safety, tolerability, and dose response
- Vasospasm patients’ human pilot trial: all patients resolved vasospasm (fully or partially) and all survived after a single stimulation
- NIH-sponsored early feasibility clinical trial for treatment of ischemic stroke in the emergency department – first patient enrollment expected during Q3 2024
- Ten scientific papers published to date
Increase in brain perfusion index after one stimulation in blue; and after two stimulations 120 minutes apart in red.
Approach to Market
Publications
- Facial nerve stimulation as a future treatment for ischemic stroke
- Effects of Noninvasive Facial Nerve Stimulation in the Dog Middle Cerebral Artery Occlusion Model of Ischemic Stroke
- Restored Brain Perfusion after Non-Invasive Stimulation of the Facial Nerve in a Canine Stroke Model
- Effect of pulsed magnetic stimulation of the facial nerve on cerebral blood flow